Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development, effective January 22, 2019.
| RICHMOND, Calif. /PRNewswire/ -- Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development, effective January 22, 2019. Dr. Woolfson will oversee discovery, research and development activities for the Company and will report to Sandy Macrae.
“This is a meaningful time to welcome Adrian to Sangamo, as we expect a significant flow of clinical data from our genomic medicines programs throughout 2019 and will advance new programs into first-in-human studies,” said Sandy Macrae, Sangamo’s Chief Executive Officer. “Adrian’s extensive experience in research, translational medicine and drug development will be instrumental in guiding our therapeutic development strategy and leading Sangamo’s growth into a late-stage development company in the upcoming years.” Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio encompassing a broad range of immuno-modulatory agents focused on the Pfizer/Merck KGaA PD-L1 inhibitor avelumab and 4-1BB agonist utomilumab. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb initially in London, UK where he launched the TKI dasatinib, and then in Princeton, New Jersey, where he was Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor. Before joining industry, Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke’s Hospital Cambridge in the UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University in the UK. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. His doctoral and post-doctoral work on alternative splicing, soluble CD antigens, and protein folding was in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK. About Sangamo Therapeutics Forward-Looking Statements
SOURCE Sangamo Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:SGMO |
View original content to download multimedia:
